EGFR and adenocarcinoma: EGFR‐TKIs had been proven to offer prolonged progression‐free survival (PFS) and better life quality than chemotherapy in advanced NSCLC patients with EGFR mutations in many clinical trials,3, 4, 5, 6, 7, 8, 9, 10 in which most of the patients were adenocarcinoma.